Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + cisplatin for 6 cycles versus docetaxel + cisplatin for 3 cycles followed by docetaxel alone for 3 cycles in first-line advanced non-small-cell lung cancer
2007-002625-77Phase 2Terminated
- Sponsor
- Fondazione Giglio
- Start
- Jul 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fondazione Giglio. Primary endpoints: Antitumor activity and Safety. Started Jul 2007; status: terminated.
02
Drugs
docetaxelcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-002625-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002625-77.